SLS - SELLAS Life Sciences Group Inc. PEG Multiple
The expected pricing power upon the approval of the Galinpepimut-S vaccine creates powerful growth potential for SELLAS Life Sciences (SLS). The peg_co ratio demonstrates current dynamics, where the 0.00 mark reflects the asset's current state. Diversification through the fight against leukemia minimizes risks, while the status of an innovative yet speculative developer maintains high price volatility amid expectations for clinical trial results.
Analytical breakdowns for SELLAS Life Sciences (SLS)
- market price and analyst price targets:
- market capitalization statistics:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient SELLAS Life Sciences|SLS - Long-Term Debt to Capital|Current Liabilities to Capital sellaslifesciences.com|SLS - Company Debts|Debt to Book Capitalization Ratio SELLAS Life Sciences Group Inc.|SLS - Company Long-Term Debt|Company Short-Term Debt SELLAS Life Sciences|Quick Ratio sellaslifesciences.com
- earnings and valuation multiples information:
SLS - Company Net Income|Company Profit Forecast SELLAS Life Sciences|SLS - Price to Earnings Ratio|Future Price to Earnings Multiple sellaslifesciences.com|SLS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SELLAS Life Sciences Group Inc.|SLS - Operating profit EBITDA|Net earnings per share for the last four quarters SELLAS Life Sciences|SLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share trend for the last twelve months sellaslifesciences.com|SLS - Earnings growth in current year|Expected net earnings per share growth next year SELLAS Life Sciences
Fundamental company analysis:SELLAS Life Sciences Group, Inc. SLS
The SELLAS Life Sciences biotech ecosystem possesses high market potential, yet full product commercialization is constrained by pending FDA approvals. This metric compares market value with profit growth rates, where values below one signal that the asset is undervalued, enabling the identification of promising entry points through an analysis of the PEG ratio.
Competitors of SELLAS Life Sciences
Price/Earnings to Growth Multiple BeiGene Ltd. ONC|Halozyme Inc. - Price/Earnings to Growth Multiple|PEG Multiple Revolution Medicines Corp RVMD|AAPG - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio CGON (cgoncology.com)|URGN: PEG Multiple|Price to Earnings Adjusted for Growth Rate Bicara Therapeutics Inc (BCAX)|Price/Earnings to Growth Ratio Personalis Corp|Erasca Oncology (ERAS) - Growth-Adjusted Market Cap to Net Income|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Aura Biosciences AURA|Candel Therapeutics Inc. - Price/Earnings to Growth Ratio|ARAY - Price/Earnings to Growth Ratio|ACTU: Price/Earnings to Growth Ratio|CTOR: PEG Multiple|TuHURA Biosciences (HURA) - PEG Multiple|Price/Earnings to Growth Ratio Protara Therapeutics, Inc.|Fate Therapeutics Inc (FATE) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Champions Oncology, Inc. CSBR|XBiotech Inc - Price/Earnings to Growth Ratio|CEL-SCI Corp - PEG Multiple|Growth-Adjusted Market Cap to Net Income OS Therapies Inc. OSTX|RADX: PEG Multiple|Market Cap to Earnings and Growth Ratio ARTV (Artiva Biotherapeutics)|ANL (Adlai Nortye Ltd) - PEG Multiple|Price to Earnings Adjusted for Growth Rate verupharma.com VERU|Price/Earnings to Growth Multiple TPST (Tempest Therapeutics, Inc.)|XLO (xiliotx.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Renovaro RENB|Growth-Adjusted Market Cap to Net Income Mural Oncology PLC (MURA)|Kairos Pharma Inc - PEG Multiple|OnKure Therapeutics Inc (OKUR) - Price/Earnings to Growth Multiple|GDTC: PEG Multiple|CRIS - Growth-Adjusted Market Cap to Net Income|APLM (Apollomics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Tharimmune Corporation THAR|Price/Earnings to Growth Ratio Advanced Biomed Inc (ADVB)|genprex.com - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate Salarius Pharma|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|AONC - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio BeiGene|Checkpoint Therapeutics Inc. (CKPT) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Elevation Oncology, Inc. (ELEV)|Price/Earnings to Growth Ratio ICAD (icadmed.com)|Price/Earnings to Growth Ratio Ikena Oncology IKNA|Growth-Adjusted Market Cap to Net Income notablelabs.com (NTBL)|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA: PEG Multiple|Ascentage (AAPGV) - PEG Multiple
